Treatment of toxic epidermal necrolysis: the uncertainty persists but the fog is dispersing

Editorial

Klaus Wolff et al. Arch Dermatol. 2003 Jan.

. 2003 Jan;139(1):85-6.

doi: 10.1001/archderm.139.1.85.

No abstract available

Comment in

Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis.
Trent JT, Kerdel FA. Trent JT, et al. Arch Dermatol. 2003 Aug;139(8):1081. doi: 10.1001/archderm.139.8.1081-a. Arch Dermatol. 2003. PMID: 12925403 No abstract available.

Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases.
Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE; TEN-IVIG Study Group. Toxic epidermal necrolysis-intravenous immunoglobulin. Prins C, et al. Arch Dermatol. 2003 Jan;139(1):26-32. doi: 10.1001/archderm.139.1.26. Arch Dermatol. 2003. PMID: 12533160
Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression.
Bachot N, Revuz J, Roujeau JC. Bachot N, et al. Arch Dermatol. 2003 Jan;139(1):33-6. doi: 10.1001/archderm.139.1.33. Arch Dermatol. 2003. PMID: 12533161 Clinical Trial.
Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience.
Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Trent JT, et al. Arch Dermatol. 2003 Jan;139(1):39-43. doi: 10.1001/archderm.139.1.39. Arch Dermatol. 2003. PMID: 12533162